Dermatomyosıtıs and lymphoma

Year 2021, Volume: 31 Issue: 1, 98 - 100, 31.01.2021

Dilek Tezcan Muhammet Limon Semral Gülcemal Sema Yılmaz

Abstract

Dermatomyositis is an idiopathic inflammatory myopathy which is characterized by progressive proximal muscle weakness and specific skin manifestations. Although the relationship between idiopathic myositis with cancer is well known, particularly patients with dermatomyositis accompanying malignancy has the highest risk .Older age, extensive and severe skin involvement, necrotic skin lesions, rapidly progressive severe muscle weakness, and elevated serum creatine kinase level enhance the risk of malignancy. The most common encountered malignancies are ovarian, lung, breast, stomach and colorectal cancer. Dermatomyositis related hematological malignancy is less common, but patients have poor prognosis. In this artricle, We present the case to emphasize that lymphoma may be accompanied by DM patients

Keywords

Dermatomyositis, malignancy, lymphoma

Dermatomiyozit ve Lenfoma Birlikteliği

Abstract

Dermatomiyozit, progresif seyirli proksimal kas güçsüzlüğü ve özgül deri bulgularıyla karakterize idiyopatik inflamatuvar bir miyopatidir. İdiyopatik miyozitler ile kanser ilişkisi iyi bilinmekle birlikte, özellikle dermatomiyozitli hastalar eşlik eden malignite açısından en yüksek riske sahiptir. İleri yaş, yaygın ve şiddetli deri tutulumu, nekrotik deri lezyonları, hızlı ilerleyen şiddetli kas güçsüzlüğü ve serum kreatin kinaz seviyesindeki yükseklik kanser görülme riskini artırmaktadır. En sık rastlanan maligniteler over, akciğer, meme, mide ve kolorektal kanserdir. Dermatomiyozit ile ilişkili hematolojik malignitesi daha az görülmekle birlikte hastaların prognozu kötüdür. Dermatomiyozit hastalarına lenfomanın da eşlik edebileceği bu olgumuzda vurgulanmak istenmiştir

Keywords

Dermatomiyozit, malignite, lenfoma

References

• Grundtman, Cecilia, Vivianne Malmström, Ingrid Lund- berg. ‘Immune mechanisms in the pathogenesis of idio- pathic inflammatory myopathies.’ Arthritis Res Therapy 2007;208.
• Andersen LK, Davis MD.‘ Prevalence of Skin and SkinRe- lated Diseases in the Rochester Epidemiology Project and a Comparison with Other Published Prevalence Studies.’ Dermatology; 2016;232:344-52.
• Edition Mosby Elsevier. 2015 5. Callen JP, Wortmann RL. ‘Dermatomyositis.’ Clin Dermatol 2006;24:363-73.
• Bohan A, Peter JB: ‘Polymyositis and dermatomyositis.’ N Engl J Med 1975;292:344-7.
• Kamalı S. ‘Dirençli inflamatuar miyozitli olgulara klinik yaklaşım: Romatoloji perspektifi.’ RAED Dergisi 2011;3:57- 60.
• Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 1976; 84:68.
• Bivalacqua TJ, Alphs H, Aksentijevich I, et al. Paraneoplas- tic polyarthritis from non-small-cell lung cancer metastatic to the bladder. J Clin Oncol 2007; 25:2621.
• Stertz O. Polymyositis. Berl Klin Wochenschr 1916; 53:489.
• Wang J, Guo G, Chen G, et al: Meta-analysis of the associa- tion of dermato- myositis and polymyositis with cancer. Br J Dermatol 2013;169:838-47.
• Chen YJ, Wu CY, Huang YL, et al. Cancer risks of derma- tomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010; 12:R70.
• Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoanti- body to a 155-kd protein is associated with dermatomyosi- tis. Arthritis Rheum 2006; 54:3682.
• Marie I , Guillevin L , Menard JF et al. Hematological ma- lignancy associated with polymyositis and dermatomyosi- tis.Autoimmun Rev.2012 ; 11: 615-20.
• Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have an- tibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65:2954.
• Ceribelli A, Isailovic N, De Santis M, et al. Myositis-spe- cific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol. 2017;36:469-75.
• Joerg-Patrick Stübgen. İnflamatuar miyopatiler ve lenfoma J Neurol Sci 2016; 369: 377-89.